Urticaria Chronic
7
2
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
14.3%
1 terminated out of 7 trials
80.0%
-6.6% vs benchmark
14%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (7)
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
Mediterranean and Low-Histamine Diets for Pediatric Chronic Spontaneous Urticaria
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
Detection of Viral Particels in Urticaria Patients
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients
Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)